Ali Behbahani Sells 13,679 Shares of CRISPR Therapeutics (NASDAQ:CRSP) Stock

Key Points

• Director Ali Behbahani sold 13,679 CRISPR Therapeutics shares at an average price of $57.09, generating $780,934 and reducing his position by 45.12% to 16,637 shares.
• CRISPR Therapeutics shares rose 3.1% to $58.33, while the company reported a quarterly loss of $0.94 per share on $10.18 million in revenue and analysts expect a full-year loss of $4.47 per share.
• Analyst sentiment remains broadly positive, with a “Moderate Buy” consensus and an average price target of $67.94; institutional investors own 69.2% of the company.

CRISPR Therapeutics AG (NASDAQ:CRSP - Get Free Report) Director Ali Behbahani sold 13,679 shares of the business's stock in a transaction that occurred on Thursday, September 17th. The stock was sold at an average price of $57.09, for a total value of $780,934.11. Following the transaction, the director directly owned 16,637 shares in the company, valued at $949,806.33. This trade represents a 45.12% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.

CRISPR Therapeutics Stock Up 3.1%

Shares of CRISPR Therapeutics stock traded up $1.77 on Monday, reaching $58.33. 1,813,544 shares of the company were exchanged, compared to its average volume of 1,761,454. The company has a market capitalization of $5.64 billion, a price-to-earnings ratio of -12.25 and a beta of 1.76. The company has a current ratio of 17.85, a quick ratio of 17.85 and a debt-to-equity ratio of 0.34. CRISPR Therapeutics AG has a one year low of $44.12 and a one year high of $78.48. The company has a 50-day moving average of $53.08 and a 200 day moving average of $52.77.

CRISPR Therapeutics (NASDAQ:CRSP - Get Free Report) last released its earnings results on Tuesday, June 30th. The company reported ($0.94) earnings per share for the quarter. CRISPR Therapeutics had a negative net margin of 3,368.72% and a negative return on equity of 24.39%. The firm had revenue of $10.18 million during the quarter. On average, equities research analysts forecast that CRISPR Therapeutics AG will post -4.47 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of brokerages have recently issued reports on CRSP. Needham & Company LLC reaffirmed a "buy" rating and issued a $82.00 target price on shares of CRISPR Therapeutics in a report on Monday, August 31st. Citigroup reiterated a "market outperform" rating on shares of CRISPR Therapeutics in a report on Tuesday, August 25th. HC Wainwright reissued a "buy" rating on shares of CRISPR Therapeutics in a research report on Monday, August 31st. The Goldman Sachs Group restated a "neutral" rating and issued a $55.00 price objective on shares of CRISPR Therapeutics in a research note on Thursday, August 6th. Finally, Citizens Jmp reaffirmed a "market outperform" rating and issued a $80.00 price objective on shares of CRISPR Therapeutics in a research report on Monday, August 31st. One analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, six have given a Hold rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat.com, CRISPR Therapeutics currently has an average rating of "Moderate Buy" and an average price target of $67.94.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the stock. Norges Bank bought a new position in shares of CRISPR Therapeutics during the fourth quarter worth approximately $25,706,000. Canal Insurance CO bought a new stake in CRISPR Therapeutics in the 1st quarter valued at $1,670,000. Quantinno Capital Management LP grew its holdings in CRISPR Therapeutics by 613.5% in the 1st quarter. Quantinno Capital Management LP now owns 47,989 shares of the company's stock valued at $2,283,000 after buying an additional 41,263 shares in the last quarter. Blue Jean Financial LLC acquired a new position in CRISPR Therapeutics in the 4th quarter valued at $1,470,000. Finally, KBC Group NV increased its position in CRISPR Therapeutics by 3,999.9% during the 1st quarter. KBC Group NV now owns 116,847 shares of the company's stock worth $5,558,000 after buying an additional 113,997 shares during the period. Institutional investors and hedge funds own 69.20% of the company's stock.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics AG NASDAQ: CRSP is a biotechnology company focused on developing gene-editing medicines using CRISPR/Cas9 technology. The company's programs are designed to modify disease-associated genes in human cells, with the goal of treating serious conditions across hematology, oncology, autoimmune disease and regenerative medicine.

Its most advanced product is Casgevy (exa-cel), an autologous cell therapy developed in collaboration with Vertex Pharmaceuticals. Casgevy uses CRISPR/Cas9 gene editing to modify a patient's blood stem cells and is approved in several markets for eligible patients with sickle cell disease and transfusion-dependent beta thalassemia.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.